Loading...
XNASRGLS
Market cap100mUSD
Dec 24, Last price  
1.54USD
1D
0.65%
1Q
-3.14%
Jan 2017
-94.30%
IPO
-96.94%
Name

Regulus Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:RGLS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
85.13%
Rev. gr., 5y
-8.71%
Revenues
0k
8,601,00013,789,00012,700,00019,569,0007,669,00020,759,0001,194,00072,00072,0006,832,00010,006,000000
Net income
-30m
L+6.05%
-15,559,000-7,602,000-17,408,000-18,668,000-56,680,000-55,748,000-81,836,000-71,905,000-48,709,000-18,592,000-15,263,000-27,808,000-28,323,000-30,037,000
CFO
-27m
L+4.87%
12,307,000-15,063,000-8,721,000-28,330,000-39,510,000-49,859,000-56,882,000-58,773,000-43,273,000-19,821,000-12,536,000-24,128,000-25,526,000-26,768,000
Earnings
Mar 19, 2025

Profile

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
URL
https://www.regulusrx.com/
IPO date
Oct 04, 2012
Employees
30
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
52,261
28,361
28,275
Unusual Expense (Income)
NOPBT
(52,261)
(28,361)
(28,275)
NOPBT Margin
Operating Taxes
1,000
1,000
1,000
Tax Rate
NOPAT
(52,262)
(28,362)
(28,276)
Net income
(30,037)
6.05%
(28,323)
1.85%
(27,808)
82.19%
Dividends
Dividend yield
Proceeds from repurchase of equity
15,120
4,491
53,791
BB yield
-62.30%
-21.48%
-1,992.49%
Debt
Debt current
1,334
4,511
589
Long-term debt
2,110
3,536
9,507
Deferred revenue
Other long-term liabilities
1,179
Net debt
(20,323)
(31,113)
(50,287)
Cash flow
Cash from operating activities
(26,768)
(25,526)
(24,128)
CAPEX
(613)
(361)
(251)
Cash from investing activities
14,491
(15,120)
(251)
Cash from financing activities
11,816
4,491
53,737
FCF
(52,225)
(27,878)
(30,863)
Balance
Cash
23,767
39,160
60,383
Long term investments
Excess cash
23,767
39,160
60,383
Stockholders' equity
(513,188)
(483,166)
(454,702)
Invested Capital
536,764
522,736
518,518
ROIC
ROCE
EV
Common stock shares outstanding
18,960
15,260
8,570
Price
1.28
-6.57%
1.37
334.92%
0.32
-76.67%
Market cap
24,269
16.09%
20,906
674.39%
2,700
-42.83%
EV
3,951
(10,202)
(47,582)
EBITDA
(52,034)
(28,239)
(27,816)
EV/EBITDA
0.36
1.71
Interest
604
688
855
Interest/NOPBT